Language Outcomes, Mechanisms, and Trajectories in Adults With and Without Developmental Language Disorder
Launched by UNIVERSITY OF IOWA · Mar 25, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how adults with Developmental Language Disorder (DLD) compare to those with typical language skills, focusing on their long-term language abilities and the underlying reasons for any differences. Researchers are looking at data from a previous study that followed individuals from childhood into adulthood, specifically targeting those aged 30 to 35. They want to see how language skills evolve over time, whether some individuals with DLD catch up to their peers, or if others may experience difficulties or remain stable in their language abilities.
To participate, you need to be an adult aged 28 to 40 who has either DLD or typical language skills and has previously taken part in the Iowa Longitudinal Study. Participants will undergo various assessments to understand their language performance and cognitive skills. Importantly, you should have normal or corrected vision and hearing, and you should not have a history of brain injury or other developmental disabilities. If you join the study, you can expect to contribute to important research that helps improve our understanding of language development and communication challenges in adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults with Developmental Language Disorder (DLD) and those with typical language (TL) between the ages of 28 and 40 years who participated in the Iowa Longitudinal Study(NIH-DC-19-90 \& P50 DC002746; IRB# 200106051, "Collaboration on Specific Language Impairment".)
- • Aged 30-35
- • Normal or corrected to normal vision
- • Normal hearing
- Exclusion Criteria:
- • history of brain injury
- • history of neural developmental disabilities
- • not monolingual
About University Of Iowa
The University of Iowa, a leading academic and research institution, is dedicated to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university harnesses the expertise of its faculty and researchers to investigate cutting-edge therapies and treatments across various medical fields. Committed to ethical research practices and patient-centered care, the University of Iowa strives to contribute significantly to medical knowledge and improve health outcomes through rigorous scientific inquiry and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Trial Officials
Stewart McCauley, PhD
Principal Investigator
University of Iowa
Si On Yoon, PhD
Principal Investigator
University of Iowa
Philip Combiths, PhD
Principal Investigator
University of Iowa
J. Bruce Tomblin, PhD
Principal Investigator
University of Iowa
Jacob Oleson, PhD
Principal Investigator
University of Iowa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported